As of September 30, 2025, unrestricted cash and cash equivalents and investments in marketable debt securities totaled $133.6 million. The Company expects its cash, cash equivalents, and investments in marketable debt securities will be sufficient to fund operations into mid-2027.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
- Protara Therapeutics Advances Phase 2 Study for Bladder Cancer Treatment
- Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment
- Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations
- Optimistic Outlook for Protara Therapeutics: Buy Rating Driven by Promising TARA-002 Developments and Strategic Opportunities